Kala Pharmaceuticals, Inc. KALA 深 滬
已收盤 09-26 16:00:00 美东时间
19.05
+0.830
+4.56%
華盛通- 最 高19.4799
- 今 開18.90
- 成交量 39.54万股
- 最 低 18.34
- 昨 收 18.22
- 總市值 1.34亿
- 52周最高 20.60
- 市盈率 靜 --
- 換手率 5.63%
- 52周最低 2.92
- 委 比 35.58%
- 總股本 702.10万
- 歷史最高 1337.50
- 量 比 1.56
- 振 幅 6.26%
- 歷史最低 2.92
- 每 手 1
- 風險率 3.26%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Kala Pharmaceuticals Sets Date for Annual Meeting
Kala Pharmaceuticals ( ($KALA) ) has provided an update. On September 16, 2025,...
09-19 04:50
美股大行评级 | Tigress Financial：维持苹果"强烈买入"评级，目标价升至305美元；杰富瑞维持百度"买入"评级，目标价升至157美元
今日重点评级关注：HC Wainwright & Co.：维持Astria Therapeutics"买入"评级，目标价从16美元升至20美元；HC Wainwright & Co.：维持Avalo Therapeutics"买入"评级，目标价从15美元升至25美元
09-18 10:13
HC Wainwright & Co. Maintains Buy on Kala Bio, Raises Price Target to $35
HC Wainwright & Co. analyst Yi Chen maintains Kala Bio (NASDAQ:KALA) with a Buy and raises the price target from $12 to $35.
09-17 18:34
美股大行评级 | 潜在涨幅208.48%！HC Wainwright & Co.上调Microbot Medical目标价至12美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Microbot Medical"买入"评级，目标价从9美元升至12美元；Maxim Group：维持Neuphoria Therapeutics"买入"评级，目标价从18美元升至35美元
09-12 12:53
Mizuho Initiates Coverage On Kala Bio with Outperform Rating, Announces Price Target of $30
Mizuho analyst Graig Suvannavejh initiates coverage on Kala Bio (NASDAQ:KALA) with a Outperform rating and announces Price Target of $30.
09-08 19:42
Kala Pharmaceuticals Appoints Todd Bazemore as CEO
An update from Kala Pharmaceuticals ( ($KALA) ) is now available. Kala Pharmace...
09-02 20:28
KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director
KALA BIO appoints Todd Bazemore as President and CEO, leveraging his over 30 years of experience in biopharmaceutical leadership, particularly in rare disease companies. Bazemore has served as interim CEO since February 2025 and previously as President and COO. His expertise is expected to guide KALA through a pivotal phase as it awaits Phase 2b trial results for KPI-012, a therapy for persistent corneal epithelial defect (PCED). KALA BIO focuses...
09-02 12:00
5 Healthcare Stocks On Fire This Week
Healthcare stocks SNOA, EVOK, KALA, DNA, & SNGX soar with massive momentum gains, signaling breakout potential in biotech & pharma.
08-21 20:24
Kala Bio Q2 EPS $(1.71) Beats $(1.82) Estimate
Kala Bio (NASDAQ:KALA) reported quarterly losses of $(1.71) per share which beat the analyst consensus estimate of $(1.82) by 6.04 percent. This is a 45.89 percent increase over losses of $(3.16) per share from the same
08-08 21:44
KALA BIO Non-GAAP EPS of -$1.71
KALA BIO press release (NASDAQ:KALA): Q2 Non-GAAP EPS of -$1.71. Cash resources of $31.9 million as of June 30, 2025, expected to fund operations into 1Q 2026 More on KALA BIO Seeking Alpha’s Quant Ra...
08-08 20:07
